|
Market Closed -
NSE India S.E.
07:05:10 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 1,748.00 INR | -0.57% |
|
-0.61% | +1.65% |
| Market Cap | 4,194B 44.18B 39.44B 36.4B 33.04B 61.88B 62.81B 438B 173B 2,195B 166B 162B 6,931B | P/E 2027 * |
32.5x | P/E 2028 * | 27.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3,909B 41.18B 36.76B 33.93B 30.79B 57.68B 58.55B 409B 162B 2,046B 154B 151B 6,461B | EV / Sales 2027 * |
6x | EV / Sales 2028 * | 5.28x |
| Free-Float |
44.39% | Yield 2027 * |
0.97% | Yield 2028 * | 1.14% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.57% | ||
| 1 week | -0.61% | ||
| Current month | -3.78% | ||
| 1 month | -6.27% | ||
| 3 months | -10.54% | ||
| 6 months | +4.04% | ||
| Current year | +1.65% |
| 1 week | 1,719.1 |  | 1,768.9 |
| 1 month | 1,719.1 | | 1,865 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 2025-08-31 | |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 2025-08-31 | |
| Director/Board Member | 71 | 2021-05-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.57% | -0.61% | +3.44% | +55.73% | 44.18B | |
| -2.54% | +1.31% | +54.27% | +114.96% | 1,135B | |
| -1.42% | +3.23% | +38.56% | +74.44% | 636B | |
| +0.16% | +0.08% | +25.29% | +95.23% | 505B | |
| -0.31% | +3.09% | +44.14% | +64.80% | 378B | |
| -1.34% | -0.47% | +66.04% | +41.00% | 358B | |
| -0.68% | +2.65% | +22.98% | +50.39% | 295B | |
| -1.20% | +3.04% | +2.33% | +22.86% | 266B | |
| -1.79% | +1.57% | +50.56% | +59.08% | 237B | |
| -0.73% | -0.10% | +29.02% | +99.67% | 193B | |
| Average | -1.04% | +1.89% | +33.66% | +67.82% | 404.85B | |
| Weighted average by Cap. | -1.34% | +2.63% | +40.61% | +79.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.86B 6.12B 5.65B 5.13B 9.61B 9.75B 68.06B 26.94B 341B 25.73B 25.19B 1,076B | 730B 7.69B 6.86B 6.34B 5.75B 10.77B 10.93B 76.29B 30.2B 382B 28.85B 28.24B 1,206B |
| Net income | 129B 1.36B 1.21B 1.12B 1.02B 1.9B 1.93B 13.48B 5.34B 67.51B 5.1B 4.99B 213B | 155B 1.63B 1.45B 1.34B 1.22B 2.28B 2.31B 16.15B 6.39B 80.88B 6.11B 5.98B 255B |
| Net Debt | -285B -3B -2.68B -2.47B -2.24B -4.2B -4.26B -29.76B -11.78B -149B -11.25B -11.02B -471B | -341B -3.59B -3.21B -2.96B -2.69B -5.03B -5.11B -35.65B -14.11B -179B -13.48B -13.19B -564B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-23 | ₹1,748.00 | -0.57% | 1,064,528 |
| 26-10-22 | ₹1,758.00 | +0.74% | 1,778,519 |
| 26-10-21 | ₹1,745.10 | +0.12% | 2,316,342 |
| 26-10-19 | ₹1,743.00 | -0.90% | 829,445 |
| 26-10-16 | ₹1,758.80 | -0.29% | 1,522,459 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
